Multimodal Cardiovascular and Hepatic Population Imaging
Trial Snapshot
- Phase
- Not Applicable
- Status
- Recruiting
- Sponsor
- Enrollment
- 2,400
- Locations
- 1
- Primary Endpoint
- Establishement of reference nomograms accounting for sex in diaphragm
Study Overview
Brief Summary
Medical imaging is increasingly important for understanding diseases, detecting them early, and personalizing treatments. New imaging techniques, which can measure processes in the body without surgery, are opening the door to a more precise approach to medicine. Instead of relying on general probabilities, this technology allows us to analyze specific factors in a person's health, leading to better predictions and targeted treatments. One key challenge in medicine today is reducing "residual individual risk"-the remaining health risks that current treatments don't fully address. This involves understanding how factors like age, sex, genetics, and environment affect our health, particularly when it comes to conditions like heart and liver disease. By using imaging to distinguish between normal aging and disease, we can better assess individual health risks.
The current project will create a large collection of medical images linked with health data from a broad population across France. Using advanced, non-invasive techniques such as MRI and ultrasound, researchers will analyze the heart, blood vessels, and liver in detail, considering factors like gender and health risk profiles. This will help improve our understanding of these diseases, which are often silent and not well understood, providing direct benefits to the participants. Ultimately, the goal is to optimize imaging technologies for large-scale studies, which will help enhance early detection and prevention for everyone.
Study Design
- Study Type
- Observational
- Observational Model
- Cohort
- Time Perspective
- Prospective
Eligibility Criteria
- Ages
- 20 Years to — (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- Yes
Inclusion Criteria
- •Participation to the Constances cohort
- •Age ≥ 20 years
- •No overt cardiovascular or hepatic disease or related symptoms
- •No known family or personal genetic disease
- •Affiliation with a social security scheme or beneficiary of such a scheme.
- •Agreement to sign the consent
Exclusion Criteria
- •Renal function impairment with GFR < 60 mL/min/1.73m2
- •Deprived of liberty or persons subject to a legal protection measure (under guardianship or trusteeship)
- •People with contraindications to MRI (claustrophobia, presence of metallic elements…)
- •Pregnant or breastfeeding woman (pregnancy urinary test before inclusion for women of childbearing age).
Arms & Interventions
Constances volunteers
The 2400 volunteers will be stratifed according to age in decades from 20 to 80 years of age and matched 1:1 male:female.
Intervention: Imaging examinations (Radiation)
Constances volunteers
The 2400 volunteers will be stratifed according to age in decades from 20 to 80 years of age and matched 1:1 male:female.
Intervention: Paramedical examinations (Other)
Constances volunteers
The 2400 volunteers will be stratifed according to age in decades from 20 to 80 years of age and matched 1:1 male:female.
Intervention: Medical examination (Other)
Constances volunteers
The 2400 volunteers will be stratifed according to age in decades from 20 to 80 years of age and matched 1:1 male:female.
Intervention: Echocardiography (Other)
Outcomes
Primary Outcomes
Establishement of reference nomograms accounting for sex in diaphragm
Time Frame: During 36 months of analysis (after 60 months of inclusion)
Ultrasound and MRI images analysis of diaphragm
Establishement of reference nomograms accounting for age in diaphragm
Time Frame: During 36 months of analysis (after 60 months of inclusion)
Ultrasound and MRI images analysis of diaphragm
Establishement of reference nomograms accounting for sex in kidney
Time Frame: During 36 months of analysis (after 60 months of inclusion)
Ultrasound and MRI images analysis of kidney
Establishement of reference nomograms accounting for age in heart
Time Frame: During 36 months of analysis (after 60 months of inclusion)
Ultrasound and MRI images analysis of qualitative and quantitative morphology, function, quantitative tissue characterization of the heart
Establishement of reference nomograms accounting for sex in heart
Time Frame: During 36 months of analysis (after 60 months of inclusion)
Ultrasound and MRI images analysis of qualitative and quantitative morphology, function, quantitative tissue characterization of the heart
Establishement of reference nomograms accounting for age in liver
Time Frame: During 36 months of analysis (after 60 months of inclusion)
Ultrasound and MRI images analysis of quantitative steatosis, fibrosis
Establishement of reference nomograms accounting for sex in liver
Time Frame: During 36 months of analysis (after 60 months of inclusion)
Ultrasound and MRI images analysis of quantitative steatosis, fibrosis
Establishement of reference nomograms accounting for age in adipose tissue
Time Frame: During 36 months of analysis (after 60 months of inclusion)
Ultrasound and MRI images analysis of volumes of subcutaneous, visceral and epicardial adipose tissues
Establishement of reference nomograms accounting for sex in adipose tissue
Time Frame: During 36 months of analysis (after 60 months of inclusion)
Ultrasound and MRI images analysis of volumes of subcutaneous, visceral and epicardial adipose tissues
Secondary Outcomes
- Advanced Imaging profiling of Heart(During 36 months of analysis (after 60 months of inclusion))
- Advanced imaging profiling in Liver(During 36 months of analysis (after 60 months of inclusion))
- Advanced biological phenotyping(During 36 months of analysis (after 60 months of inclusion))
- identification of genetic risk markers for cardio-metabolic diseases(During 36 months of analysis (after 60 months of inclusion))